Latest Conference Articles

March 27th 2021, 1:57pm

European Lung Cancer Congress

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

March 26th 2021, 11:25pm

HCC-TAG Conference

Although the combination of atezolizumab and bevacizumab has become the standard frontline treatment for patients with advanced hepatocellular carcinoma, whether immunotherapy could play a role in earlier lines of treatment remains the subject of ongoing research.

March 26th 2021, 11:13pm

HCC-TAG Conference

Combinations of checkpoint inhibitors and VEGF TKIs, as well as dual checkpoint blockade, are affording patients with advanced hepatocellular carcinoma greater potential for disease control and deep, long-lasting responses, underscoring the need for biomarkers of response to combination regimens and single-agent TKIs, the latter of which still play a role for select populations.

March 26th 2021, 10:58pm

European Lung Cancer Congress

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.

March 26th 2021, 10:54pm

European Lung Cancer Congress

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

March 26th 2021, 10:25pm

European Lung Cancer Congress

Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.

March 26th 2021, 10:23pm

European Lung Cancer Congress

Previous exposure to immune checkpoint inhibitors or osimertinib has been linked with poor outcomes in patients with non–small cell lung cancer who were receiving a subsequent atezolizumab-containing regimen.

March 26th 2021, 9:00pm

HCC-TAG Conference

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

March 26th 2021, 8:35pm

European Lung Cancer Congress

The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer.

March 25th 2021, 9:55pm

European Lung Cancer Congress

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

March 25th 2021, 9:31pm

European Lung Cancer Congress

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

March 25th 2021, 8:15pm

European Lung Cancer Congress

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

March 25th 2021, 6:58pm

European Lung Cancer Congress

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

March 25th 2021, 6:48pm

European Lung Cancer Congress

The frontline combination of nivolumab and ipilimumab plus 2 cycles of chemotherapy demonstrated an improvement in overall survival vs chemotherapy alone in patients with advanced non–small cell lung cancer regardless of tumor mutational burden status in the tissue or blood.

March 24th 2021, 7:55pm

SGO Annual Meeting

Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.

March 24th 2021, 3:00pm

School of Gastrointestinal Oncology

Racial disparities affecting all aspects of patient care are a major issue across cancer types, including for patients with gastrointestinal cancers.

March 23rd 2021, 7:15pm

School of Gastrointestinal Oncology

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

March 22nd 2021, 9:56pm

SGO Annual Meeting

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

March 20th 2021, 2:45am

SGO Annual Meeting

The combination of pembrolizumab and lenvatinib improved progression-free and overall survival, as well as response rates, compared with chemotherapy in patients with advanced endometrial cancer who received prior platinum-based chemotherapy, irrespective of mismatch repair status, according to phase 3 findings of the Study-309/KEYNOTE-775 trial.

March 17th 2021, 9:08pm

EBMT Meeting

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.